Kim Papp
Impact in
- Dermatology top 0.01%
- Dermatology and Skin Diseases
- Immunology top 0.01%
- Psoriasis: Treatment and Pathogenesis
Papers in
- Immunology 374
- Psoriasis: Treatment and Pathogenesis 358
- Dermatology 140
- Dermatology and Skin Diseases 130
- Co-authors
- Richard G. Langley (55 shared papers)Kristian Reich (63 shared papers)Kenneth B. Gordon (46 shared papers)Craig L. Leonardi (24 shared papers)C.E.M. Griffiths (34 shared papers)Shu Li (10 shared papers)Melinda Gooderham (118 shared papers)Alan Menter (35 shared papers)
- Journals
- Journal of the American Academy of Dermatology (97 papers)British Journal of Dermatology (62 papers)Journal of Cutaneous Medicine and Surgery (51 papers)Journal of the European Academy of Dermatology and Venereology (39 papers)Annals of the Rheumatic Diseases (28 papers)
- Partner nations
- CanadaUnited StatesGermany
In The Last Decade
Kim Papp
517 papers receiving 32.4k citations
Kim Papp's Hit Papers
Peers
Comparison fields: 5 of 148
- Dermatology 11.0k
- Immunology 22.6k
- Rheumatology 5.9k
- Immunology and Allergy 1.9k
- Hematology 2.6k
Countries citing papers authored by Kim Papp
This map shows the geographic impact of Kim Papp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Papp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Papp more than expected).
Fields of papers citing papers by Kim Papp
This network shows the impact of papers produced by Kim Papp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Papp. The network helps show where Kim Papp may publish in the future.
Co-authors
The 25 scholars most cited alongside Kim Papp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 547 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials Hit paper breakdown → | 2014 | 1511 |
| 2 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Hit paper breakdown → | 2008 | 1438 |
| 3 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Hit paper breakdown → | 2008 | 1070 |
| 4 | Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial Hit paper breakdown → | 2005 | 855 |
| 5 | Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial Hit paper breakdown → | 2005 | 837 |
| 6 | Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis Hit paper breakdown → | 2012 | 734 |
| 7 | Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial Hit paper breakdown → | 2007 | 698 |
| 8 | Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis Hit paper breakdown → | 2016 | 666 |
| 9 | Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials Hit paper breakdown → | 2015 | 664 |
| 10 | Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial Hit paper breakdown → | 2017 | 650 |
| 11 | Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) Hit paper breakdown → | 2007 | 562 |
| 12 | A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Hit paper breakdown → | 2005 | 559 |
| 13 | Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) Hit paper breakdown → | 2015 | 488 |
| 14 | Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials Hit paper breakdown → | 2018 | 470 |
| 15 | Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study Hit paper breakdown → | 2009 | 464 |
| 16 | Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials Hit paper breakdown → | 2017 | 425 |
| 17 | 2006 | 422 | |
| 18 | 2017 | 401 | |
| 19 | 2016 | 384 | |
| 20 | Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics Hit paper breakdown → | 2013 | 380 |
About Kim Papp
Kim Papp is a scholar working on Immunology, Dermatology, Rheumatology, Pathology and Forensic Medicine and Immunology and Allergy, having authored 547 papers that have together received 33.2k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (358 papers), Dermatology and Skin Diseases (130 papers), Autoimmune Bullous Skin Diseases (40 papers), Pharmaceutical studies and practices (38 papers), Spondyloarthritis Studies and Treatments (36 papers), Asthma and respiratory diseases (28 papers), Allergic Rhinitis and Sensitization (25 papers) and Health Systems, Economic Evaluations, Quality of Life (23 papers). The work is most often cited by research in Dermatology (11.0k citations), Immunology (22.6k citations), Rheumatology (5.9k citations), Immunology and Allergy (1.9k citations) and Hematology (2.6k citations). Kim Papp has collaborated with scholars based in Canada, United States and Germany. Frequent co-authors include Richard G. Langley, Kristian Reich, Kenneth B. Gordon, Craig L. Leonardi, C.E.M. Griffiths, Shu Li, Melinda Gooderham, Alan Menter, Andrew Blauvelt and Cynthia Guzzo. Their work appears in journals such as Journal of the American Academy of Dermatology, British Journal of Dermatology, Journal of Cutaneous Medicine and Surgery, Journal of the European Academy of Dermatology and Venereology and Annals of the Rheumatic Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.